The screening kits were developed using miRNAs for high-risk populations for urothelial carcinoma (UC). Products 702703 are designed for chronic kidney diseasehemodialysis patients using urineblood samples, respectively. With high accuracyminimal invasiveness, the kits are intended to be used as a screeningregular monitoring of UC. If a test reveals a positive result, the patient then undergoes cystoscopic examination for further confirmation. Otherwise, the patent only needs to be monitored annually.

We constructed a model to differentiate different neurodegenerative diseases by using blood-based biomarkers. Linear Discriminant Analysis (LDA) was used to reduce dimensionsMICE (Multivariate Imputation by Chained Equations) was used for missing value treatmentchoose CART model to predict missing value imputation. This machine learning model would be used for early dectection of neurodegenerative diseases.

We based on ion trap for mass filter so that ultra-high vacuum is not needed to reduce the weightsize. We took frequency scanning to increase our mass range by 10,000,000,000. We used LED as LC detector to reduce sizecost. Therefore, we not only made a portable device but also a device with many special advantages in technology. An advanced analytical lab can become mobile to easily reach anywhere which needs in-situreal-time analysis by our inventions.